JAKAFI XR vs UPADACITINIB

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 21, 2026·How we rate

Possible drug interaction. JAKAFI XR and UPADACITINIB are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	JAKAFI XR	UPADACITINIB
Rating	New	68/100
Pharmacy pays	—	—
Type	RX	RX
Active ingredient	RUXOLITINIB PHOSPHATE	UPADACITINIB
Manufacturer	Incyte Corp	Sandoz
Dosage forms	Tablet, extended release	Tablet, extended release, Tablet
Drug class	Janus Kinase Inhibitor	Janus Kinase Inhibitor
Boxed warning	None	None
Half-life	—	about 8 to 14 hours (mean terminal elimination half-life)
Treats	Polycythemia Vera, Primary Myelofibrosis	Rheumatoid Arthritis

jakafi xr upadacitinib

Rating

New

68/100

Pharmacy pays

—

Type

Active ingredient

RUXOLITINIB PHOSPHATE

UPADACITINIB

Manufacturer

Incyte Corp

Sandoz

Dosage forms

Tablet, extended release

Tablet, extended release, Tablet

Drug class

Janus Kinase Inhibitor

Boxed warning

None

Half-life

—

about 8 to 14 hours (mean terminal elimination half-life)

Treats

Polycythemia Vera, Primary Myelofibrosis

Rheumatoid Arthritis

Frequently asked questions

What is the difference between Jakafi XR and Upadacitinib?

Jakafi XR contains Ruxolitinib Phosphate, while Upadacitinib contains Upadacitinib — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.